Management of High Grade Dysplasia patients
| Cancer Alliance | National | ||
|---|---|---|---|
| Number of High Grade Dysplasia patients in audit | 63 | 1120 | |
| Cancer Alliance | National | ||
| Method of Diagnosis | |||
| – First diagnosis confirmed by second pathologist | N/A | 100.0% | 90.0% |
| Treatment planning | |||
| – HGD plan discussed at MDT | N/A | 90.5% | 93.0% |
| – Treatment plan for active treatment | N/A | 78.0% | 82.0% |
| First treatment | |||
| – Endoscopic therapy (such as endoscopic resection) | N/A | 76.0% | 78.0% |
| – Surveillance | N/A | 18.0% | 11.0% |
NOTE: Percentages have been calculated based on the number of patients with recorded data for each variable and not the total number of patients in the Cancer Alliance.
Management of oesophago-gastric cancer patients
| Organisation | National | ||
|---|---|---|---|
| Number of oesophago-gastric (OG) cancer patients in audit | 95 | 19,865 | |
| Case ascertainment for OG cancer (%) | 85-100% | ||
| Method of Diagnosis | |||
| – Patients diagnosed after an emergency admission** ** Percent figure accounts for differences in mix of patients across organisations |
<10 | 5.2% | 13.1% |
| – Patients with referral source reported as unknown | 0 | 0.0% | 1.4% |
| Pre-treatment staging of cancer | |||
| – Patients having staging CT scan recorded | 77 | 81.1% | 94.0% |
| Treatment planning | |||
| – Patients having a plan for curative treatment | 47 | 49.5% | 37.2% |
| – Patients having a plan for non-curative treatment | 48 | 50.5% | 62.8% |
| – Patients with non-curative plans having chemotherapy or radiotherapy | N/A | 34.7% | |